In the last three months, 4 analysts have published ratings on Lantheus Holdings (NASDAQ:LNTH), offering a diverse range of perspectives from bullish to bearish.

The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.

	Bullish	Somewhat Bullish	Indifferent	Somewhat Bearish	Bearish
Total Ratings	2	2	0	0	0
Last 30D	0	1	0	0	0
1M Ago	0	0	0	0	0
2M Ago	0	0	0	0	0
3M Ago	2	1	0	0	0

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $78.0, along with a high estimate of $82.00 and a low estimate of $72.00. This current average reflects an increase of 13.87% from the previous average price target of $68.50.

Analyzing Analyst Ratings: A Detailed Breakdown

An in-depth analysis of recent analyst actions unveils how financial experts perceive Lantheus Holdings. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst	Analyst Firm	Action Taken	Rating	Current Price Target	Prior Price Target
David Turkaly	Citizens	Raises	Market Outperform	$78.00	$73.00
Richard Newitter	Truist Securities	Raises	Buy	$82.00	$80.00
Anthony Petrone	Mizuho	Raises	Outperform	$72.00	$60.00
Richard Newitter	Truist Securities	Raises	Buy	$80.00	$61.00

Key Insights:

• Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Lantheus Holdings. This information provides a snapshot of how analysts perceive the current state of the company.
• Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Lantheus Holdings compared to the broader market.
• Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Lantheus Holdings's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.

Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Lantheus Holdings's market standing. Stay informed and make data-driven decisions with our Ratings Table.

Stay up to date on Lantheus Holdings analyst ratings.

Discovering Lantheus Holdings: A Closer Look

Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.

Lantheus Holdings: Delving into Financials

Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.

Revenue Growth: Lantheus Holdings's remarkable performance in 3M is evident. As of 30 September, 2025, the company achieved an impressive revenue growth rate of 1.39%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Lantheus Holdings's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 7.23% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): Lantheus Holdings's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 2.43%, the company may encounter challenges in delivering satisfactory returns for shareholders.

Return on Assets (ROA): Lantheus Holdings's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.26% ROA, the company effectively utilizes its assets for optimal returns.

Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.55.

Understanding the Relevance of Analyst Ratings

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

This article was generated by Benzinga's automated content engine and reviewed by an editor.